List of Small Molecule Pharmaceuticals Companies in Ireland - 29

Alkermes seeks to develop innovative medicines that help address the unmet needs and challenges of people living with debilitating diseases. As a fully-integrated, global biopharmaceutical company, Alkermes applies its scientific expertise, proprietary technologies and global resources to develop products that are designed to make a meaningful difference in the way patients manage their disease.

Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. For more information, visit www.amarincorp.com. See our Community Guidelines: bit.ly/2L7xEW6

Amryt Pharma was acquired by Chiesi Farmaceutici S.p.A. (“Chiesi”) April 12, 2023. Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

AnaBio Technologies is a biotechnology company based in Ireland that specializes in microencapsulation technologies. The company enhances the delivery and effectiveness of sensitive bioactive ingredients, focusing on precision nutrition solutions for both human and animal health. Founded by Dr. Sinéad Bleiel, AnaBio originated from her PhD research and has grown to employ around 20–27 staff, generating reported revenue of $6.4 million. AnaBio offers a range of services, including microencapsulation technology that protects ingredients like probiotics and vitamins from degradation. They develop customized formulations for controlled release, optimizing effectiveness in dietary supplements, infant nutrition, and sports recovery. Their flagship product line includes encapsulated probiotics designed to improve gut health outcomes. Additionally, AnaBio is expanding its offerings to include specialized microencapsulated ingredients for livestock and pet health. The company serves global clients across the food, pharmaceutical, and animal nutrition industries, emphasizing scientific innovation and tailored solutions.

We are a biopharmaceutical company passionately committed to providing solutions for overlooked and unmet medical needs through patient-focused, innovative products.

Cara Partners is a pharmaceutical manufacturing company that specializes in producing a standardised extract of Ginkgo Biloba, an Active Pharmaceutical Ingredient (API), in County Cork, Ireland.

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Celtic Biotech is developing novel candidate therapies for the treatment of solid cancers and pain in humans. Derived from specialised receptor binding proteins found in snake venom, these product candidates have the potential to increase survival, improve quality-of-life and reduce treatment costs for cancer patients. Celtic Biotech is focusing its research on solid tumours, including non-small-cell lung cancer (NSCLC), as its initial targets. The Company's lead candidate, CB24 (Crotoxin), has been observed to be highly toxic to various tumour cell lines in pre-clinical and early clinical studies.

Consilient Health is a pharmaceutical company with a rich heritage of commercialising medicines in areas including women’s health, urology and endocrinology. Established in 2005, Consilient Health is headquartered in Ireland with offices in the UK and Sweden (for the Nordic region) We have formed strong partnerships in Benelux and Spain and continue to expand our geographic footprint in Europe. As an independent, privately-held and profitable business with a strong balance sheet, we can make decisions quickly and are able to invest in long-term collaborations and partnerships to expand our portfolio of products and to support our partners’ objectives. Our goal is to address patients’ and healthcare professionals’ unmet needs with medicines that are differentiated and we are actively seeking to in-license late stage developments or marketed products. We do not undertake research and development and are not a manufacturer. Consilient Health deliver everything from regulatory affairs through to market access, supply chain, distribution, medical affairs, marketing and sales all underpinned by quality and compliance. Our focus is on driving value in our partners’ brands, maximizing their commercial potential, enabling them to expand their geographical footprint and providing access for patients. For more information please visit www.consilienthealth.com CORP-CH-204(2) Date of preparation July 2022

Cosmo Pharmaceuticals improve people's lives by developing innovative treatments that address significant unmet clinical needs and improve clinical outcomes in the field of gastroenterology and endoscopy. Our clinical development pipeline specifically addresses innovative treatments for gastro-intestinal diseases and Colon Infections. Our effort is aimed to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection rate of pre-cancerous lesions during colonoscopy. Along with our presence in drugs manufacturing, we have significant innovative research and operations supporting our growing portfolio of specialty products. Learn more at www.cosmopharma.com/.

Deciphex is building a global network of AI empowered pathologists, ensuring accessible, innovative pathology services that improve patient outcomes. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.

DS Biopharma was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life for people with diseases for which current therapies are unsatisfactory. Our vision is to enhance people's dignity and well-being by developing these products through a careful balance of applied pharmacology and clinical science.

We are a research-driven company that specialises in the development, manufacture and supply of a broad range of High Potency Oral Solid Dose (OSD) Human & Veterinary speciality products. Since 2006, we have built a reputation as an innovative company specialising in developing and manufacturing of film-coated tablets, soft-gel capsules, and powder or liquid-filled hard-shell capsules. Our work, which focused on successfully producing cancer chemotherapy drugs, allowed us to create strong partnerships with leading pharmaceutical companies, thus making our founders' vision a reality. In 2015, our successful track record and reputation for industry excellence prompted the acquisition of Eirgen Pharma by the OPKO Health family of companies. Becoming a part of OPKO Health has allowed Eirgen Pharma to invest further in our facilities and our people, increasing development and manufacturing capabilities. Eirgen now serves patients in more than 60 countries worldwide, including major markets such as the USA, Europe, Japan, Canada, Australia, the Middle East and Africa. Nowadays, at Eirgen Pharma's centre of excellence in Waterford, Ireland, we simplify the journey of getting your product to market by providing full turnkey CDMO services for the development, manufacture and packaging of high potency oral dose medicines for both human and veterinary use. Eirgen also holds the production rights for numerous OSD products and has the capacity to manufacture each of these products at scale.

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that is being investigated in the Phase 2 part of an ongoing Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate that is in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has a significant corporate presence in Palo Alto, CA and Philadelphia, PA and in England in London, Oxford and Cambridge, with manufacturing facilities in Ireland, England and Italy. We maintain a highly collaborative culture where employees focus on how they can be successful and accomplish positive results by exemplifying the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. Together, we are experts, analysts, specialists, advocates, scientists and professionals all with diverse backgrounds and perspectives. Working together, we are proud to support patients, innovate and bring new medicines to patients with critical unmet needs. Please see our website at www.jazzpharma.com for more information. For information on recruitment, please visit https://careers.jazzpharma.com/. For guidelines on engaging with Jazz on social media, please visit https://bit.ly/2OaMOuq.

Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering. Juvenescence has a broad pipeline in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span.

Keltic Pharma is based in a world leading laboratory in Glasgow with our highly skilled team of industrial scientists and leading academics. We work alongside commercial partners and universities to deploy novel innovative technologies in the pursuit of next generation drugs for unmet clinical needs.

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, emerging animal diseases, and, most recently, Covid-19 — as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-ireland.com

Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together.

SOSV is a global venture capital firm that operates early stage startup development programs. SOSV’s programs are focused on revolutionary deep technology that promises the betterment of humanity and the planet. The firm’s strategy is to invest in a small number of highly promising startups and use its deeply resourced programs to accelerate product development, acquire customers, and scale. SOSV companies consistently raise funding rounds led by top tier investors. SOSV joins seed, Series A, and later rounds while providing founders with ongoing support and community. As of January 2024, SOSV had more than 1,000 portfolio companies and $1.5 billion in assets under management. SOSV’s programs include hard tech-oriented HAX and life-science driven IndieBio. Both offer deep technical and scientific expertise on-site as well as well-equipped lab and fabrication facilities and supply chain access. Among the top companies in SOSV’s portfolio are NotCo, Upside Foods, Unspun, Opentrons, Mycoworks, and Prime Roots. SOSV releases the annual Human Health 100, a list of the firm’s top human health investments in areas ranging from assistive robotics to therapeutics and diagnostics. SOSV also publishes the annual Climate Tech 100, a list of the firm’s top climate-focused investments working on solutions to climate change across five sectors: food, manufacturing, transport, energy, and building systems.

Relevium Medical are a biopharmaceutical company with locations in Ireland and the US. We aspire to improve the lives of people with debilitating chronic pain conditions through creating superior treatments.

Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).

SeqBiome is a world leading microbiome contract research company, providing first in class technical and scientific services to researchers in leading companies in the Pharma, Food, and Nutrition industries and to academic researchers in top Universities. SeqBiome measures, analyzes, and interprets the microbiome using state-of-the-art tools, partnering with industry and academia to offer custom sequencing and bioinformatics services. We are committed to helping our customers derive actionable insights from their projects. SeqBiome offers an end-to-end Microbiome analysis service for our customers. We add most value to our customers by being involved early in their study and we can assist them with Statistical Study Design, Sample Processing, Metagenomic Sequencing, Compositional and Functional Microbiome Analysis, Biostatistical and Bioinformatic Analysis, and Publication/Patent Ready Outputs.

At Shorla Oncology we develop and commercialize innovative oncology drugs for women's and pediatric cancers. We focus on indications where existing treatments are limited, in shortage or inadequate for the target population. Our products are the result of Shorla's world class team encompassing thought leaders, clinicians, scientists and commercial strategists who have extensive experience in the area of drug development and commercialization of niche cancer treatments. Our growing portfolio will bring accessible, affordable and life-saving treatments to patients, delivering a major contribution to patient care and providing a significant clinical impact.

SOMAÍ Pharmaceuticals is a leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company with a global footprint of distribution for the largest and most advanced EU GMP-certified cannabinoid-containing pharmaceutical extract portfolio. At SOMAÍ, we are building a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics. We envision a world where people live a healthy lifestyle empowered by natural cannabis medicine. SOMAÍ owns a state-of-the-art manufacturing facility and indoor cultivation in Lisbon, Portugal, and has global sales teams in the largest medical cannabis markets. We are continuing to make acquisitions and global brand partnerships that make us one of a few and the first European-based vertically integrated companies in the EU able to cater to the diverse needs of fast-growing global cannabis markets.

Ulysses Neuroscience Limited is an Irish Private R&D Organisation providing clinical and preclinical research services to pharmaceutical companies.